Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses potential challenges nurses might face with the new advent on immunotherapy.
Matthew Burke, MBA, RN, MSN, APRN-BC
Advertisement
Articles by Matthew Burke, MBA, RN, MSN, APRN-BC
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses managing immune-mediated adverse events (IMAEs)
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale-New Haven Hospital, discusses the prevalence of immunotherapy-related adverse events.
Advertisement
Latest Updated Articles
Matthew Burke on the Prevalence of Immunotherapy AEsFebruary 7th 2014
Matthew Burke Discusses Adverse EventsMarch 5th 2014
- Matthew Burke on Immune-Mediated Adverse Events
May 5th 2014
Advertisement
Advertisement
Trending on Oncology Nursing News
1
AI and Oncology Nursing: Detecting Misdiagnosis With Molecular Profiling
2
FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer: What Nurses Need to Know
3
FDA Grants Traditional Approval to Selpercatinib for RET-Fusion Solid Tumors
4
Optimizing Multiple Myeloma Care: Insights From a Nursing Expert
5